Sequence specific antimicrobials
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
1. A pharmaceutical composition for killing targeted bacteria in a mixed bacterial population comprising:
a pharmaceutically acceptable carrier and
a recombinant phagemid,
wherein the recombinant phagemid comprises a clustered regularly interspaced short palindromic repeats (CRISPR) system,
wherein the CRISPR system comprises DNA encoding: i) a Type II CRISPR-associated enzyme; and ii) a targeting RNA that targets at least one bacterial chromosome at a target site; and
wherein, upon contacting a bacterial population containing the at least one bacterial chromosome with the pharmaceutical composition, the recombinant phagemid is introduced into bacteria in the bacterial population,
wherein subsequent to the introduction of the recombinant phagemid, the targeting RNA and the Type II CRISPR-associated enzyme are expressed in the bacteria into which the recombinant phagemid is introduced,
wherein the expressed Type II CRISPR-associated enzyme cleaves the bacterial chromosome at the target site of the targeting RNA, and
wherein the cleavage of the bacterial chromosome at the target site kills the bacteria.
2. The pharmaceutical composition of claim 1 , wherein the type II CRISPR-associated enzyme is a Cas9 enzyme.
3. The pharmaceutical composition of claim 2 , wherein the Cas9 enzyme is a Streptococcus pyogenes Cas9.
4. The pharmaceutical composition of claim 1 , wherein the bacteria is selected from the group consisting of Streptococcus, Staphylococcus, Clostridium, Bacillus, Salmonella, Helicobacter pylori, Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli , and any combination thereof.
5. The pharmaceutical composition of claim 4 , wherein the bacteria is Staphylococcus aureus.
6. The pharmaceutical composition of claim 5 , wherein the bacteria is a methicillin-resistant Staphylococcus aureus.
7. The pharmaceutical composition of claim 1 , wherein the Type II CRISPR system encodes at least one targeting RNA that targets a toxin gene.
8. The pharmaceutical composition of claim 1 , wherein the Type II CRISPR system encodes at least one targeting RNA that targets an S. aureus virulence gene.
9. The pharmaceutical composition of claim 8 , wherein the Type II CRISPR system encodes at least one targeting RNA that targets an enterotoxin sek gene or a mecA gene.
10. A pharmaceutical composition for killing targeted bacteria in a mixed bacterial population comprising:
a pharmaceutically acceptable carrier and
a recombinant phagemid,
wherein the recombinant phagemid comprises a clustered regularly interspaced short palindromic repeats (CRISPR) system,
wherein the CRISPR system comprises DNA encoding: i) a Type II CRISPR-associated enzyme; and ii) a targeting RNA that targets an antibiotic resistance gene on a bacterial plasmid at a target site within the bacterial plasmid;
wherein, upon contacting a bacterial population containing the antibiotic resistance gene on the bacterial plasmid with the pharmaceutical composition, the recombinant phagemid is introduced into bacteria in the bacterial population,
wherein the targeting RNA and the Type II CRISPR-associated enzyme are expressed in the bacteria into which the recombinant phagemid is introduced,
wherein the expressed Type II CRISPR-associated enzyme cleaves the antibiotic resistance gene on a bacterial plasmid at the target site within the bacterial plasmid, and
wherein the cleavage of the bacterial plasmid at the target site kills the bacteria in the presence of the antibiotic.
11. The pharmaceutical composition of claim 10 , wherein the type II CRISPR-associated enzyme is a Cas9 enzyme.
12. The pharmaceutical composition of claim 11 , wherein the Cas9 enzyme is a Streptococcus pyogenes Cas9.
13. The pharmaceutical composition of claim 10 , wherein the bacteria is selected from the group consisting of Streptococcus, Staphylococcus, Clostridium, Bacillus, Salmonella, Helicobacter pylori, Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli , and any combination thereof.
14. The pharmaceutical composition of claim 12 , wherein the bacteria is Staphylococcus aureus.
15. The pharmaceutical composition of claim 14 , wherein the bacteria is a methicillin-resistant Staphylococcus aureus.
16. The pharmaceutical composition of claim 15 , wherein the antibiotic resistance gene confers resistance to a narrow-spectrum beta-lactam antibiotic of the penicillin class of antibiotics.
17. The pharmaceutical composition of claim 16 , wherein the antibiotic resistance gene is a methicillin-resistance gene.
18. A pharmaceutical composition for killing targeted bacteria in a mixed bacterial population comprising:
a pharmaceutically acceptable carrier and
a recombinant phagemid,
wherein the recombinant phagemid comprises a clustered regularly interspaced short palindromic repeats (CRISPR) system,
wherein the CRISPR system comprises DNA encoding: i) a Type II CRISPR-associated enzyme; and ii) a targeting RNA that targets a bacterial plasmid comprising an antibiotic resistance gene at a target site within the bacterial plasmid;
wherein, upon contacting a bacterial population containing the bacterial plasmid comprising an antibiotic resistance gene with the pharmaceutical composition, the recombinant phagemid is introduced into bacteria in the bacterial population,
wherein the targeting RNA and the Type II CRISPR-associated enzyme are expressed in the bacteria into which the recombinant phagemid is introduced,
wherein the expressed Type II CRISPR-associated enzyme cleaves the bacterial plasmid comprising an antibiotic resistance gene at the target site within the bacterial plasmid, and
wherein the cleavage of the bacterial plasmid at the target site kills the bacteria in the presence of the antibiotic.
19. The pharmaceutical composition of claim 18 , wherein the type II CRISPR-associated enzyme is a Cas9 enzyme.
20. The pharmaceutical composition of claim 19 , wherein the Cas9 enzyme is a Streptococcus pyogenes Cas9.
21. The pharmaceutical composition of claim 18 , wherein the bacteria is selected from the group consisting of Streptococcus, Staphylococcus, Clostridium, Bacillus, Salmonella, Helicobacter pylori, Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli , and any combination thereof.
22. The pharmaceutical composition of claim 21 , wherein the bacteria is Staphylococcus aureus.
23. The pharmaceutical composition of claim 22 , wherein the bacteria is a methicillin-resistant Staphylococcus aureus.
24. The pharmaceutical composition of claim 18 , wherein the antibiotic resistance gene confers resistance to a narrow-spectrum beta-lactam antibiotic of the penicillin class of antibiotics.
25. The pharmaceutical composition of claim 24 , wherein the antibiotic resistance gene is a methicillin-resistance gene.